1. Short title This Act may be cited as the Fixing Global Freeloading Act . 2. Findings Congress finds the following: (1) International government price controls of pharmaceutical products and services creates an unfair playing field because the rest of the world relies on and benefits from the biopharmaceutical innovation that takes place in the United States, which supports 4.5 million jobs and amounts to $90 billion in research and development investment every year. (2) The United States pays the cost of developing innovative and life-saving prescription drugs while other countries refuse to pay their fair share for their health care needs. (3) In fact, some of the United States trading partners are ignoring obligations established under trade agreements and setting up discriminatory rules to benefit local competitors over United States companies. (4) Between 2010 and 2011, 23 countries implemented 89 distinct measures to contain government spending on prescription drugs. Most used their single-payer healthcare systems to impose drug price controls alongside increased copayments, value-added tax rates on prescription drugs, and other measures. (5) Studies have shown that government price controls result in prices below actual market value and push the burden of paying for innovative treatments on to United States patients. 3. Chief Pharmaceutical Negotiator (a) In general Section 141 of the Trade Act of 1974 ( 19 U.S.C. 2171 ) is amended— (1) in subsection (b)(2)— (A) by striking and one Chief Innovation and Intellectual Property Negotiator and inserting one Chief Innovation and Intellectual Property Negotiator, and one Chief Pharmaceutical Negotiator ; (B) by striking or the Chief Innovation and Intellectual Property Negotiator and inserting the Chief Innovation and Intellectual Property Negotiator, or the Chief Pharmaceutical Negotiator